ATE486125T1 - Verabreichung teilgereifter dendritischer zellen in vitro zur behandlung von tumoren - Google Patents
Verabreichung teilgereifter dendritischer zellen in vitro zur behandlung von tumorenInfo
- Publication number
- ATE486125T1 ATE486125T1 AT03790358T AT03790358T ATE486125T1 AT E486125 T1 ATE486125 T1 AT E486125T1 AT 03790358 T AT03790358 T AT 03790358T AT 03790358 T AT03790358 T AT 03790358T AT E486125 T1 ATE486125 T1 AT E486125T1
- Authority
- AT
- Austria
- Prior art keywords
- dendritic cells
- tumor
- cells
- partially matured
- administration
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 238000000338 in vitro Methods 0.000 title 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 210000001165 lymph node Anatomy 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000004041 dendritic cell maturation Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000035800 maturation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/50—Colon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/72—Undefined extracts from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43126702P | 2002-12-06 | 2002-12-06 | |
| PCT/US2003/038672 WO2004053072A2 (en) | 2002-12-06 | 2003-12-05 | Administration of dendritic cells partially matured in vitro for the treatment of tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE486125T1 true ATE486125T1 (de) | 2010-11-15 |
Family
ID=32507696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03790358T ATE486125T1 (de) | 2002-12-06 | 2003-12-05 | Verabreichung teilgereifter dendritischer zellen in vitro zur behandlung von tumoren |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20060057120A1 (de) |
| EP (2) | EP2260861A1 (de) |
| JP (2) | JP4859169B2 (de) |
| KR (1) | KR101144196B1 (de) |
| CN (2) | CN102600461B (de) |
| AT (1) | ATE486125T1 (de) |
| AU (2) | AU2003293411B2 (de) |
| BR (1) | BRPI0317064B8 (de) |
| CA (1) | CA2509058A1 (de) |
| DE (1) | DE60334725D1 (de) |
| DK (1) | DK1567155T3 (de) |
| ES (1) | ES2354944T3 (de) |
| IL (1) | IL169002A (de) |
| MX (1) | MXPA05006042A (de) |
| PL (1) | PL377209A1 (de) |
| PT (1) | PT1567155E (de) |
| RU (1) | RU2348418C2 (de) |
| WO (1) | WO2004053072A2 (de) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2260861A1 (de) * | 2002-12-06 | 2010-12-15 | NorthWest Biotherapeutics, Inc. | Verabreichung teilgereifter dendritischer Zellen in vitro zur Behandlung von Tumoren |
| US20070134273A1 (en) * | 2004-02-10 | 2007-06-14 | Francois Romagne | Composition and method for the treatment of carcinoma |
| US8076132B2 (en) | 2004-09-17 | 2011-12-13 | Hasumi International Research Foundation | Dendritic cell tumor injection (DCTI) therapy |
| US20060216269A1 (en) * | 2004-09-17 | 2006-09-28 | Kenichiro Hasumi | Dendritic cell tumor injection (DCTI) therapy |
| WO2006095330A2 (en) * | 2005-03-10 | 2006-09-14 | Yeda Research And Development Co. Ltd. | Methods and immunogenic cell preparations for treating antigen-associated diseases |
| WO2007001200A1 (en) * | 2005-06-23 | 2007-01-04 | Obschestvo S Ogranichennoi Otvetsvennostyu 'rusgen' | Mature dendritic cells loaded with tumor polylysates and antitumoral vaccine base thereon |
| AR060424A1 (es) * | 2007-04-11 | 2008-06-18 | Consejo Nac Invest Cient Tec | Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento |
| WO2008133595A1 (en) * | 2007-04-26 | 2008-11-06 | Newbiomed Pika Pte Ltd | Compositions and methods for stimulating an immune response in-vivo and in-vitro |
| WO2008151389A1 (en) * | 2007-06-15 | 2008-12-18 | Macfarlane Burnet Institute For Medical Research And Public Health Limited | Chemically modified macromolecules |
| EP2072617A1 (de) * | 2007-12-12 | 2009-06-24 | Trimed Biotech GmbH | Verfahren zur Herstellung dendritischer Zellen |
| RU2361598C1 (ru) * | 2008-02-18 | 2009-07-20 | Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) | Средство, индуцирующее созревание дендритных клеток |
| KR102242305B1 (ko) * | 2008-03-27 | 2021-04-19 | 아스테리아스 바이오세라퓨틱스, 인크. | 영장류 다능성 줄기 세포의 조혈계 세포로의 분화 |
| CN107007626A (zh) * | 2009-07-09 | 2017-08-04 | 蒂盖尼克斯公司 | 用于细胞治疗的方法和组合物 |
| HUE028352T2 (en) * | 2010-02-10 | 2016-12-28 | Immunicum Ab | An improved composition for inhibiting tumor cell proliferation |
| WO2011115970A1 (en) * | 2010-03-15 | 2011-09-22 | The Trustees Of The University Of Pennsylvania | System and method of preparing and storing activated mature dendritic cells |
| RU2530523C2 (ru) * | 2012-03-29 | 2014-10-10 | Олег Борисович Егоров | Способ противоопухолевой иммунотерапии |
| WO2014004809A2 (en) * | 2012-06-27 | 2014-01-03 | Hasumi International Research Foundation | Therapy and method for intratumorally introducing cytotoxic t lymphocyte and/or nkt cell with anti-tnf and/or anti-il-10 |
| GB201300049D0 (en) * | 2013-01-03 | 2013-02-20 | Transimmune Ag | Method for obtaining immuno-stimulatory dendritic cells |
| IL292510A (en) | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| GB201413665D0 (en) | 2014-07-03 | 2014-09-17 | Transimmune Ag And Yale University | Method for obtaining globally activated monocytes |
| AU2016286112B2 (en) * | 2015-06-30 | 2023-02-16 | Northwest Biotherapeutics, Inc. | Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response |
| US20190046568A1 (en) | 2015-09-15 | 2019-02-14 | Northwest Biotherapeutics, Inc. | Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers |
| KR101749165B1 (ko) * | 2016-06-07 | 2017-06-23 | 충남대학교산학협력단 | Rv2299c 또는 Rv2299c와 ESAT-6 융합한 단백질을 포함하는 수지상 세포의 성숙화 촉진용 조성물 |
| WO2018160666A1 (en) * | 2017-02-28 | 2018-09-07 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Short-term activated dc1s and methods for their production and use |
| GB201711379D0 (en) * | 2017-07-14 | 2017-08-30 | Univ Cape Town | Maturation of dendritic cells |
| CN109957548B (zh) * | 2017-12-26 | 2022-03-18 | 上海尚泰生物技术有限公司 | 一种基因修饰的树突状细胞疫苗 |
| GB2624871A (en) * | 2022-11-29 | 2024-06-05 | Alv B As | Process for preparing a population of dendritic cells and immunotherapy using the same |
| WO2025052001A1 (en) | 2023-09-07 | 2025-03-13 | Mnemo Therapeutics | Methods and compositions for improving immune response |
| EP4520334A1 (de) | 2023-09-07 | 2025-03-12 | Mnemo Therapeutics | Verfahren und zusammensetzungen zur verbesserung der immunreaktion |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5A (en) * | 1836-08-10 | Thomas Blanchard | Machine for mortising solid wooden shells of ships' tackle-blocks | |
| PT633929E (pt) | 1992-04-01 | 2004-07-30 | Merix Bioscience Inc | Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios |
| US5788963A (en) * | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| EP0922758B1 (de) * | 1997-10-27 | 2009-04-15 | Rockefeller University | Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen |
| US6797488B1 (en) * | 1997-12-08 | 2004-09-28 | Beth Israel Deaconess Medical Center | Methods of producing anti-angiogenic proteins |
| AU6144499A (en) * | 1998-09-15 | 2000-04-03 | University Of Pittsburgh | In situ injection of antigen-presenting cells with genetically enhanced cytokineexpression |
| NZ511118A (en) * | 1998-10-02 | 2002-11-26 | Mitsubishi Chem Corp | Activation of cellular immunity with antigenic proteins and hydrophobized polysaccharides, which have modified alkyl or cholesterol groups |
| US6649158B1 (en) * | 1998-10-15 | 2003-11-18 | Canji, Inc. | Methods and compositions to induce antitumor response |
| US6558951B1 (en) * | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
| CN1367688A (zh) * | 1999-04-14 | 2002-09-04 | 美国政府卫生与公众服务部 | 用于诱导对移植物的免疫耐受性的、包含免疫毒素和抑制树突细胞成熟的因子的组合物 |
| EP1254953A4 (de) * | 1999-12-28 | 2004-06-02 | Toyoshima Kumao | Reife auslösendes agenz für unreife dendritische zellen |
| AU5976001A (en) * | 2000-05-12 | 2001-11-26 | Northwest Biotherapeutics Inc | Method to increase class i presentation of exogenous antigens by human dendriticcells |
| JP2002069001A (ja) * | 2000-08-29 | 2002-03-08 | Asahi Kasei Corp | 樹状細胞を主成分とする細胞ワクチン |
| US7405076B2 (en) * | 2000-11-14 | 2008-07-29 | Universite Libre De Bruxelles | Generation and use of dendritic cells |
| US20020094545A1 (en) | 2000-11-30 | 2002-07-18 | Harris Paul E. | Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads |
| AU2002326463A1 (en) * | 2001-07-25 | 2003-02-17 | Northwest Biotherapeutics, Inc. | Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors |
| NZ531530A (en) * | 2001-09-06 | 2007-01-26 | Northwest Biotherapeutics Inc | Compositions and methods for priming monocytic dendritic cells and T cells for TH-1 response using BCG and IFN gamma |
| EP2260861A1 (de) * | 2002-12-06 | 2010-12-15 | NorthWest Biotherapeutics, Inc. | Verabreichung teilgereifter dendritischer Zellen in vitro zur Behandlung von Tumoren |
| EP1604016B1 (de) * | 2003-02-27 | 2009-01-14 | NorthWest Biotherapeutics, Inc. | Erzeugung dendritischer zellen aus monozytischen dendritischen vorläuferzellen mit gm-csf ohne anwesenheit zusätzlicher zytokine |
-
2003
- 2003-12-05 EP EP20100176476 patent/EP2260861A1/de not_active Ceased
- 2003-12-05 CN CN201210027703.4A patent/CN102600461B/zh not_active Expired - Fee Related
- 2003-12-05 EP EP03790358A patent/EP1567155B1/de not_active Expired - Lifetime
- 2003-12-05 RU RU2005121256/14A patent/RU2348418C2/ru active IP Right Revival
- 2003-12-05 JP JP2004559310A patent/JP4859169B2/ja not_active Expired - Lifetime
- 2003-12-05 CA CA002509058A patent/CA2509058A1/en not_active Expired - Lifetime
- 2003-12-05 AU AU2003293411A patent/AU2003293411B2/en not_active Ceased
- 2003-12-05 ES ES03790358T patent/ES2354944T3/es not_active Expired - Lifetime
- 2003-12-05 AT AT03790358T patent/ATE486125T1/de active
- 2003-12-05 CN CN2003801089756A patent/CN1738619B/zh not_active Expired - Fee Related
- 2003-12-05 DE DE60334725T patent/DE60334725D1/de not_active Expired - Lifetime
- 2003-12-05 DK DK03790358.0T patent/DK1567155T3/da active
- 2003-12-05 PL PL377209A patent/PL377209A1/pl not_active Application Discontinuation
- 2003-12-05 KR KR1020057010303A patent/KR101144196B1/ko not_active Expired - Fee Related
- 2003-12-05 US US10/538,226 patent/US20060057120A1/en not_active Abandoned
- 2003-12-05 WO PCT/US2003/038672 patent/WO2004053072A2/en not_active Ceased
- 2003-12-05 MX MXPA05006042A patent/MXPA05006042A/es active IP Right Grant
- 2003-12-05 BR BRPI0317064A patent/BRPI0317064B8/pt not_active IP Right Cessation
- 2003-12-05 PT PT03790358T patent/PT1567155E/pt unknown
-
2005
- 2005-06-05 IL IL169002A patent/IL169002A/en active IP Right Grant
-
2011
- 2011-01-28 AU AU2011200352A patent/AU2011200352B2/en not_active Ceased
- 2011-09-08 JP JP2011196385A patent/JP5707284B2/ja not_active Expired - Fee Related
-
2012
- 2012-06-04 US US13/488,388 patent/US20120251561A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE486125T1 (de) | Verabreichung teilgereifter dendritischer zellen in vitro zur behandlung von tumoren | |
| Okamoto et al. | Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation | |
| Bilsborough et al. | Mucosal CD8α+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties | |
| Han et al. | Vitamin E supplementation increases T helper 1 cytokine production in old mice infected with influenza virus | |
| Lazarski et al. | IL-4 attenuates Th1-associated chemokine expression and Th1 trafficking to inflamed tissues and limits pathogen clearance | |
| Ito et al. | TLR9 regulates the mycobacteria-elicited pulmonary granulomatous immune response in mice through DC-derived Notch ligand delta-like 4 | |
| Handel-Fernandez et al. | Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-gamma production in mammary tumor-bearing mice. | |
| CA2483012A1 (en) | Oligonucleotide compositions and their use for the modulation of immune responses | |
| Salio et al. | Dendritic cell maturation is induced by mycoplasma infection but not by necrotic cells | |
| EA200401405A1 (ru) | Модифицированный осповакцинный вирус анкара для вакцинации новорожденных | |
| DK0585943T3 (da) | Opløselige ligander for CD40 | |
| Hotz et al. | Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses | |
| ATE389712T1 (de) | Krebs immuntherapie mit semi-allogenen zellen | |
| JP2019509264A (ja) | ワクチンアジュバントとしての間葉系幹細胞及びそれを使用するための方法 | |
| Zeng et al. | Natural killer cells play a key role in the antitumor immunity generated by chaperone‐rich cell lysate vaccination | |
| MX2023001622A (es) | Celulas dendriticas optimamente activadas que inducen una respuesta inmunologica antitumoral mayor o mejorada. | |
| YU40796A (sh) | Preparati i postupci za tretiranje obolenja koja izazivaju t ćelije | |
| Holzer et al. | Haptens as drugs: contact allergens are powerful topical immunomodulators | |
| Valaperti et al. | Vaccination with Flt3L-induced CD8α+ dendritic cells prevents CD4+ T helper cell-mediated experimental autoimmune myocarditis | |
| ATE381942T1 (de) | Mittel zur behandlung von infektionen mit leishmanien | |
| Saito et al. | Characterization of the indirect antitumor effect of γ-interferon using ascites-associated macrophages in a human tumor clonogenic assay | |
| Enioutina et al. | The induction of systemic and mucosal immunity to protein vaccines delivered through skin sites exposed to UVB | |
| DE60135232D1 (de) | Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen | |
| Bergler-Czop et al. | Seborrhoeic dermatitis and a herpes zoster infection developed during treatment with adalimumab due to Crohn’s disease | |
| Saenz | The functional biology of IL-25 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1567155 Country of ref document: EP |